Nordic family office reaps rewards of new investment strategy

The family behind pharmaceutical firm Orifarm had a profit of just under DKK 40m (EUR 5.4m) from its family office, Habico Invest, in 2021. Private equity and alternative investments brought the result up.

Peter Brink Madsen has run Habico Invest since 2019. | Photo: Habico Invest / PR

Hans Bøgh-Sørensen and his family, who are behind pharmaceutical company Orifarm, had a good investment year in 2021.

”2021 was a very good year, during which we generated good returns despite writing off some old investments,” says Peter Brink Madsen, CEO of the family’s private investment company Habico Invest.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

Wide range of AUM declines among Nordic asset managers in Q2

Q2 OVERVIEW: Although the three best-performing Q1 managers have yet to release figures for this period, AMWatch’s preliminary overview suggests that the results are reflective of local market conditions, where two countries had a clear advantage.

CEO appoints new J. Lauritzen investment team

Kristian Mørch, the former CEO of Odfjell and current CEO of investment firm J. Lauritzen, has already constructed his new team, which involves both shipping and investment industry professionals.

Further reading

Related articles

Latest news

AMWatch job

See all jobs

See all jobs

Watch job

See all jobs

See all jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch